54346-19-9

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-2-METHYLTHIOPYRAZOLO[1,5-A]1,3,5-TRIAZINE is used as a chemical intermediate for the development of new pharmaceutical compounds, leveraging its unique structure and properties to create novel drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-CHLORO-2-METHYLTHIOPYRAZOLO[1,5-A]1,3,5-TRIAZINE serves as a key component in the synthesis of new agrochemicals, potentially contributing to the development of innovative pesticides or other agricultural products that enhance crop protection and yield.
Used in Organic Chemistry Research:
4-CHLORO-2-METHYLTHIOPYRAZOLO[1,5-A]1,3,5-TRIAZINE is utilized as a reactant or catalyst in various organic synthesis processes, facilitating the creation of complex organic molecules for use in different scientific and industrial applications.
Used as a Starting Material in Organic Synthesis:
4-CHLORO-2-METHYLTHIOPYRAZOLO[1,5-A]1,3,5-TRIAZINE is employed as a starting material for the synthesis of other complex organic compounds, providing a foundation for the development of new chemical entities with diverse applications across various industries.

InChI:InChI=1/C6H5ClN4S/c1-12-6-9-4-2-3-8-11(4)5(7)10-6/h2-3H,1H3

Upstream product

• 54346-18-8 2-(methylsulfanyl)-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
• 54346-18-8 2-(methylsulfanyl)pyrazolo[1,5-a][1,3,5]triazin-4-ol 
• 34682-99-0 2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one 
• 34682-99-0 2-sulfanylpyrazolo[1,5-a][1,3,5]triazin-4-ol 
• 34683-00-6 ethyl N-[(1H-pyrazol-5-yl)carbamothioyl]carbamate 
• 34683-00-6 N-[(1H-pyrazol-3-ylamino)thioxomethyl]carbamic acid ethyl ester 

Downstream Products

• 515880-10-1 4-(N-methyl-N-phenylamino)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine 
• 1162654-55-8 4-(N-methyl-N-phenylamino)-2-(methylsulfonyl)pyrazolo[1,5-a]-1,3,5-triazine 
• 1358769-17-1 C₁₉H₂₆N₆O₂ 
• 1358769-19-3 C₂₄H₂₅Br₂N₇O 
• 1358769-23-9 C₂₄H₂₄Br₂ClN₇O 
• 1548342-62-6 (S)-5-chloro-2-(1-(2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)pyrrolidin-2-yl)-3-phenylpyrrolo[1,2-f][1,2,4]triazin-4(3H)-one 
• 1548336-72-6 (S)-2-(1-(2-aminopyrazolo[1,5-a][1,3,5]triazin-4-yl)pyrrolidin-2-yl)-5-chloro-3-phenylpyrrolo[1,2-f][1,2,4]triazin-4(3H)-one 
• 54346-33-7 8-bromo-2-(methylthio)-4-chloropyrazolo<1,5-a>-1,3,5-triazine 

Relevant academic research and scientific papers

Microwave-assisted sequential one-pot synthesis of 8-substituted pyrazolo[1,5-a][1,3,5]triazines

This paper reports a convenient sequential one-pot approach for the synthesis of an array of 14 pyrazolo[1,5-a][1,3,5]triazines, substituted in C8 by halogen (Br), various functions (CN and CO2Et)2 and alkyl or (het)aryl groups. This study conf

Adenosine receptor antagonists

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.

Chemical Validation of DegS As a Target for the Development of Antibiotics with a Novel Mode of Action

Despite the availability of hundreds of antibiotic drugs, infectious diseases continue to remain one of the most notorious health issues. In addition, the disparity between the spread of multidrug-resistant pathogens and the development of novel classes of antibiotics exemplify an important unmet medical need that can only be addressed by identifying novel targets. Herein we demonstrate, by the development of the first in vivo active DegS inhibitors based on a pyrazolo[1,5-a]-1,3,5-triazine scaffold, that the serine protease DegS and the cell envelope stress-response pathway σE represent a target for generating antibiotics with a novel mode of action. Moreover, DegS inhibition is synergistic with well-established membrane-perturbing antibiotics, thereby opening promising avenues for rational antibiotic drug design.

Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS

The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS

A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, inc

Pyrazolopyrimidin CK2 and related heterocyclic compound as an inhibitor

The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:

COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM

The present invention is related to novel compounds of formula (I) having antibacterial activity against Clostridium bacteria, in particular Clostridium perfringens, pharmaceutical compositions comprising these compounds, and chemical processes for prepar

COMPOUNDS WITH ANTIBACTERIAL ACTIVITY AGAINST CLOSTRIDIUM

The present invention is related to novel compounds of formula (I) having antibacterial activity against Clostridium bacteria, in particular Clostridium perfringens, pharmaceutical compositions comprising these compounds, and chemical processes for prepar

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.